Ketone Production With Acute Caffeine Intake

July 18, 2023 updated by: Université de Sherbrooke

Stimulate the Ketogenesis by Using a Caffeine Supplement

Evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the production of ketones in healthy adults (N=10).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The aim of the study is to evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the production of ketones in healthy adults (N=10). Two different doses of caffeine (2.5 mg/kg of BW and 5 mg/kg of BW) are compared. All the participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H4C4
        • Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy adults
  • 18 years old and over

Exclusion Criteria:

  • Drinking more than 300 mg of caffeine per day
  • Diabetes or prediabetes
  • Abnormal liver and kidney function
  • Uncontrolled dyslipidemia, blood pressure
  • Use of drugs known to influence the metabolism of lipids and carbohydrates (steroid, beta-blockers, diuretics, insulin sensitizer, etc.)
  • Severe inflammation or infection
  • Pregnancy
  • Smoking

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ketonemia following caffeine intake

Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.

Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)
Dietary supplement: Control
4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
Other Names:
  • CTL
Dietary supplement: Caffeine low dose
4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
Dietary supplement: Caffeine high dose
4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma Acetoacetate Concentrations
Time Frame: 4 hours
Plasma acetoacetate (µmol/L) measured over a 4 hour period.
4 hours
Plasma Beta-hydroxybutyrate Concentrations
Time Frame: 4 hours
Plasma beta-hydroxybutyrate (µmol/L) measured over a 4 hour period.
4 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma Glucose Concentrations
Time Frame: 4 hours
Plasma glucose (mmol/L) measured over a 4 hour period.
4 hours
Plasma Cholesterol Concentrations
Time Frame: 4 hours
Plasma cholesterol (mmol/L) measured over a 4 hour period.
4 hours
Plasma Triglyceride Concentrations
Time Frame: 4 hours
Plasma triglycerides (mmol/L) measured over a 4 hour period.
4 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université de Sherbrooke

Investigators

  • Principal Investigator: Stephen Cunnane, PhD, Research Centre on Aging - CSSS-IUGS - CIUSSS de l'Estrie - CHUS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Actual)

January 1, 2015

Study Completion (Actual)

June 1, 2015

Study Registration Dates

First Submitted

February 9, 2016

First Submitted That Met QC Criteria

February 23, 2016

First Posted (Estimated)

February 29, 2016

Study Record Updates

Last Update Posted (Actual)

July 27, 2023

Last Update Submitted That Met QC Criteria

July 18, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2014-441

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Adults

Clinical Trials on Control

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe